A Phase II Study of Sorafenib Combined with Conventional Therapies in Refractory Central Nervous System Leukemia

0
9
To explore the efficacy of sorafenib combined with conventional therapies for refractory central nervous system leukemia, a Phase II study was conducted.
[Cancer]
Abstract